Laurion Capital Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-3,186
Closed -$249K – 314
2025
Q2
$249K Buy
+3,186
New +$238K ﹤0.01% 309
2024
Q3
– Sell
-8,753
Closed -$809K – 403
2024
Q2
$809K Buy
+8,753
New +$775K 0.01% 312
2022
Q2
– Sell
-4,270
Closed -$503K – 552
2022
Q1
$503K Buy
+4,270
New +$479K 0.01% 302
2021
Q2
– Sell
-50,000
Closed -$4.18M – 782
2021
Q1
$4.18M Sell
50,000
-323,622
-87% -$27.4M 0.02% 354
2020
Q4
$34.1M Buy
+373,622
New +$31M 0.26% 91
2020
Q1
– Sell
-103,026
Closed -$8.01M – 854
2019
Q4
$8.01M Buy
+103,026
New +$8.04M 0.06% 251
2019
Q3
– Sell
-29,481
Closed -$1.81M – 1092
2019
Q2
$1.81M Buy
+29,481
New +$1.78M 0.02% 434
2019
Q1
– Sell
-118,047
Closed -$6.03M – 969
2018
Q4
$6.03M Buy
118,047
+106,533
+925% +$5.39M 0.11% 243
2018
Q3
$668K Buy
+11,514
New +$563K 0.01% 772
2016
Q4
– Sell
-9,000
Closed -$362K – 1154
2016
Q3
$362K Sell
9,000
-1,500
-14% -$56.5K ﹤0.01% 696
2016
Q2
$349K Sell
10,500
-17,100
-62% -$585K 0.01% 626
2016
Q1
$812K Buy
+27,600
New +$762K 0.01% 464

Other funds holding EW

Laurion Capital Management's EW Position: Q3 2025 in Review

Laurion Capital Management sold out of Edwards Lifesciences (EW) in Q3 2025, closing a stake of 3,186 shares — an estimated $249K sold.

Laurion Capital Management first reported a position in EW in Q1 2016 and held it in 12 quarters. The position peaked at $34.1M in Q4 2020. 1,255 funds tracked by Wall St. Rank hold EW as of Q3 2025.

  • Laurion Capital Management reported no remaining Edwards Lifesciences position as of Q3 2025 after selling out during the quarter.
  • Laurion Capital Management sold 3,186 Edwards Lifesciences shares in Q3 2025, an estimated $249K.
  • Laurion Capital Management first reported a position in Edwards Lifesciences in Q1 2016 and held it in 12 quarters.
  • Laurion Capital Management's Edwards Lifesciences position peaked at $34.1M in Q4 2020.
  • 1,255 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2025.

Based on Laurion Capital Management's 13F filing for Q3 2025, filed 17 Nov 2025.